Chronic hepatitis C: Clinical and immunological features and the effect of interferon treatment

A. Pár, M. Paal, A. Gogl, J. Gervain, J. Szekeres-Barthó, J. Sipos, T. Bero, E. Hutter, G. Y. Berenci, I. Hollos, I. Kadas, G. Hegedus, G. Y. Brasch, I. Szabolcsi, G. Mózsik

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Clinical and immunological findings on 74 patients with chronic hepatitis C are reported and experiences with interferon-alpha treatment of 31 patients are summarized. The transfusion history was noted in 69% of patients and the time elapsed from the transfusion to the diagnosis was a mean of 7.15 ± 8.1 years. Concerning the severity of the liver disease, chronic persistent hepatitis was in 40%, active hepatitis in 45% and cirrhosis in 15% of the patients. Cholestasis was recorded in 32% of the cases. A significant elevation of serum immunoglobulin levels was noted in 83%, an antibody to liver-specific protein (anti-LSP) occurred in 80%, cryoglobulinaemia in 44% and circulating immune complexes in 33% of the patients. Natural killer cell activity of peripheral blood mononuclear cells significantly decreased. HLA B8 and DR3 antigens were found with increased frequency (36.6% and 42.1%). Recombinant interferon-alpha at a weekly dose of 3MU thrice, for six months, normalized serum alanine aminotransferase in 45% of patients and a sustained remission was found in 26%. The treatment resulted in the clearance of HCV-RNA from the serum in 40% of patients and that correlated well with the complete remission. In the good responders, a decrease in CD4+ cell count and a transient decrease in CD8+ cell count, as well as a moderate rise in B cell count were seen during the treatment. Mitogen-induced lymphoproliferative response and natural killer cell activity increased. Predictors of response were as follows: female sex, shorter time elapsed from transfusion, absence of HLA A1, B8, DR3 and serum anti HBc negativity.

Original languageEnglish
Pages (from-to)115-127
Number of pages13
JournalInternational Journal of Immunotherapy
Volume11
Issue number3
Publication statusPublished - 1995

Fingerprint

Chronic Hepatitis C
Interferons
HLA-B8 Antigen
Serum
Interferon-alpha
Natural Killer Cells
Therapeutics
Cell Count
HLA-A1 Antigen
HLA-DR3 Antigen
Cryoglobulinemia
Cholestasis
Chronic Hepatitis
CD4 Lymphocyte Count
Antigen-Antibody Complex
Alanine Transaminase
Mitogens
Hepatitis
Immunoglobulins
Liver Diseases

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Chronic hepatitis C : Clinical and immunological features and the effect of interferon treatment. / Pár, A.; Paal, M.; Gogl, A.; Gervain, J.; Szekeres-Barthó, J.; Sipos, J.; Bero, T.; Hutter, E.; Berenci, G. Y.; Hollos, I.; Kadas, I.; Hegedus, G.; Brasch, G. Y.; Szabolcsi, I.; Mózsik, G.

In: International Journal of Immunotherapy, Vol. 11, No. 3, 1995, p. 115-127.

Research output: Contribution to journalArticle

Pár, A, Paal, M, Gogl, A, Gervain, J, Szekeres-Barthó, J, Sipos, J, Bero, T, Hutter, E, Berenci, GY, Hollos, I, Kadas, I, Hegedus, G, Brasch, GY, Szabolcsi, I & Mózsik, G 1995, 'Chronic hepatitis C: Clinical and immunological features and the effect of interferon treatment', International Journal of Immunotherapy, vol. 11, no. 3, pp. 115-127.
Pár, A. ; Paal, M. ; Gogl, A. ; Gervain, J. ; Szekeres-Barthó, J. ; Sipos, J. ; Bero, T. ; Hutter, E. ; Berenci, G. Y. ; Hollos, I. ; Kadas, I. ; Hegedus, G. ; Brasch, G. Y. ; Szabolcsi, I. ; Mózsik, G. / Chronic hepatitis C : Clinical and immunological features and the effect of interferon treatment. In: International Journal of Immunotherapy. 1995 ; Vol. 11, No. 3. pp. 115-127.
@article{6cee5551fd6540bf9ae58a992a04b3b5,
title = "Chronic hepatitis C: Clinical and immunological features and the effect of interferon treatment",
abstract = "Clinical and immunological findings on 74 patients with chronic hepatitis C are reported and experiences with interferon-alpha treatment of 31 patients are summarized. The transfusion history was noted in 69{\%} of patients and the time elapsed from the transfusion to the diagnosis was a mean of 7.15 ± 8.1 years. Concerning the severity of the liver disease, chronic persistent hepatitis was in 40{\%}, active hepatitis in 45{\%} and cirrhosis in 15{\%} of the patients. Cholestasis was recorded in 32{\%} of the cases. A significant elevation of serum immunoglobulin levels was noted in 83{\%}, an antibody to liver-specific protein (anti-LSP) occurred in 80{\%}, cryoglobulinaemia in 44{\%} and circulating immune complexes in 33{\%} of the patients. Natural killer cell activity of peripheral blood mononuclear cells significantly decreased. HLA B8 and DR3 antigens were found with increased frequency (36.6{\%} and 42.1{\%}). Recombinant interferon-alpha at a weekly dose of 3MU thrice, for six months, normalized serum alanine aminotransferase in 45{\%} of patients and a sustained remission was found in 26{\%}. The treatment resulted in the clearance of HCV-RNA from the serum in 40{\%} of patients and that correlated well with the complete remission. In the good responders, a decrease in CD4+ cell count and a transient decrease in CD8+ cell count, as well as a moderate rise in B cell count were seen during the treatment. Mitogen-induced lymphoproliferative response and natural killer cell activity increased. Predictors of response were as follows: female sex, shorter time elapsed from transfusion, absence of HLA A1, B8, DR3 and serum anti HBc negativity.",
author = "A. P{\'a}r and M. Paal and A. Gogl and J. Gervain and J. Szekeres-Barth{\'o} and J. Sipos and T. Bero and E. Hutter and Berenci, {G. Y.} and I. Hollos and I. Kadas and G. Hegedus and Brasch, {G. Y.} and I. Szabolcsi and G. M{\'o}zsik",
year = "1995",
language = "English",
volume = "11",
pages = "115--127",
journal = "International Journal of Immunotherapy",
issn = "0255-9625",
publisher = "Bioscience Ediprint Inc.",
number = "3",

}

TY - JOUR

T1 - Chronic hepatitis C

T2 - Clinical and immunological features and the effect of interferon treatment

AU - Pár, A.

AU - Paal, M.

AU - Gogl, A.

AU - Gervain, J.

AU - Szekeres-Barthó, J.

AU - Sipos, J.

AU - Bero, T.

AU - Hutter, E.

AU - Berenci, G. Y.

AU - Hollos, I.

AU - Kadas, I.

AU - Hegedus, G.

AU - Brasch, G. Y.

AU - Szabolcsi, I.

AU - Mózsik, G.

PY - 1995

Y1 - 1995

N2 - Clinical and immunological findings on 74 patients with chronic hepatitis C are reported and experiences with interferon-alpha treatment of 31 patients are summarized. The transfusion history was noted in 69% of patients and the time elapsed from the transfusion to the diagnosis was a mean of 7.15 ± 8.1 years. Concerning the severity of the liver disease, chronic persistent hepatitis was in 40%, active hepatitis in 45% and cirrhosis in 15% of the patients. Cholestasis was recorded in 32% of the cases. A significant elevation of serum immunoglobulin levels was noted in 83%, an antibody to liver-specific protein (anti-LSP) occurred in 80%, cryoglobulinaemia in 44% and circulating immune complexes in 33% of the patients. Natural killer cell activity of peripheral blood mononuclear cells significantly decreased. HLA B8 and DR3 antigens were found with increased frequency (36.6% and 42.1%). Recombinant interferon-alpha at a weekly dose of 3MU thrice, for six months, normalized serum alanine aminotransferase in 45% of patients and a sustained remission was found in 26%. The treatment resulted in the clearance of HCV-RNA from the serum in 40% of patients and that correlated well with the complete remission. In the good responders, a decrease in CD4+ cell count and a transient decrease in CD8+ cell count, as well as a moderate rise in B cell count were seen during the treatment. Mitogen-induced lymphoproliferative response and natural killer cell activity increased. Predictors of response were as follows: female sex, shorter time elapsed from transfusion, absence of HLA A1, B8, DR3 and serum anti HBc negativity.

AB - Clinical and immunological findings on 74 patients with chronic hepatitis C are reported and experiences with interferon-alpha treatment of 31 patients are summarized. The transfusion history was noted in 69% of patients and the time elapsed from the transfusion to the diagnosis was a mean of 7.15 ± 8.1 years. Concerning the severity of the liver disease, chronic persistent hepatitis was in 40%, active hepatitis in 45% and cirrhosis in 15% of the patients. Cholestasis was recorded in 32% of the cases. A significant elevation of serum immunoglobulin levels was noted in 83%, an antibody to liver-specific protein (anti-LSP) occurred in 80%, cryoglobulinaemia in 44% and circulating immune complexes in 33% of the patients. Natural killer cell activity of peripheral blood mononuclear cells significantly decreased. HLA B8 and DR3 antigens were found with increased frequency (36.6% and 42.1%). Recombinant interferon-alpha at a weekly dose of 3MU thrice, for six months, normalized serum alanine aminotransferase in 45% of patients and a sustained remission was found in 26%. The treatment resulted in the clearance of HCV-RNA from the serum in 40% of patients and that correlated well with the complete remission. In the good responders, a decrease in CD4+ cell count and a transient decrease in CD8+ cell count, as well as a moderate rise in B cell count were seen during the treatment. Mitogen-induced lymphoproliferative response and natural killer cell activity increased. Predictors of response were as follows: female sex, shorter time elapsed from transfusion, absence of HLA A1, B8, DR3 and serum anti HBc negativity.

UR - http://www.scopus.com/inward/record.url?scp=0029620501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029620501&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029620501

VL - 11

SP - 115

EP - 127

JO - International Journal of Immunotherapy

JF - International Journal of Immunotherapy

SN - 0255-9625

IS - 3

ER -